Tactile Medical to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 17, 2026

(NasdaqGM:TCMD), MINNEAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that fourth quarter and fiscal year 2025 financial results will be released after the market closes on Tuesday, February 17, 2026. Management will host […]

VirTra to Demonstrate Next-Generation Drone Defense Marksmanship Training for Corrections at American Correctional Association Winter Conference

(NASDAQ:VTSI), CHANDLER, Ariz., Feb. 03, 2026 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, today announced it will demonstrate its next-generation Drone Defense Training System for corrections professionals at the American Correctional Association (ACA) Winter Conference, taking place February 5-8, 2026, at

InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025

(NASDAQ:INNV), DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal second quarter ended December 31, 2025. “InnovAge delivered

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

(NasdaqGM:ZNTL), SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Zentalis(R) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit

Tandy Leather Factory Announces Dividend to Stockholders

(NASDAQ:TLF), BENBROOK, Texas, Feb. 03, 2026 (GLOBE NEWSWIRE) — Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced that its Board of Directors had declared the payment of a special cash dividend to its stockholders of $0.75 per share of common stock held. The dividend will be paid on or about February 24, 2026, to stockholders

Varonis to Acquire AllTrue.ai to Manage and Secure AI Across the Enterprise

(NASDAQ:VRNS), MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (NASDAQ: VRNS), the leader in data security, today announced it is acquiring AllTrue.ai, an AI Trust, Risk, and Security Management (AI TRiSM) company that helps organizations understand and control how AI systems behave across the enterprise. AllTrue.ai brings real-time visibility and security to AI

Kandal M Venture Limited Announces Appointment of New Chief Executive Officer

(NASDAQ: FMFC), TA KHMAU, Cambodia, Feb. 03, 2026 (GLOBE NEWSWIRE) — Kandal M Venture Limited (Nasdaq: FMFC) (“Kandal” or the “Company”), a contract manufacturer of affordable luxury leather goods with manufacturing operations in Cambodia, today announced the appointment of Mr. Fok Yui Kwong as Executive Director and Chief Executive Officer, effective February 1, 2026. Mr.

PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share

(NYSE:PFLT),(TASE:PFLT.TA), MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (the “Company”) (NYSE: PFLT) declares its monthly distribution for February 2026 of $0.1025 per share, payable on March 2, 2026 to stockholders of record as of February 17, 2026. The distribution is expected to be paid from taxable net investment income. The

PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share

(NYSE:PNNT), MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) — PennantPark Investment Corporation (the “Company”) (NYSE: PNNT) declares its monthly distribution for February 2026 of $0.08 per share, payable on March 2, 2026 to stockholders of record as of February 17, 2026. The distribution is expected to be paid from taxable net investment income. The final specific

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

(NasdaqGM:FATE), SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i)

Scroll to Top